Comparative Pharmacology
Head-to-head clinical analysis: DILOR versus KAINAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR versus KAINAIR.
DILOR vs KAINAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
25 mg subcutaneously three times daily.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Category C
Category C
Bronchodilator
Bronchodilator